US Patent Issued to Ventus Therapeutics U.S. on July 8 for "Compounds for inhibiting NLRP3 and uses thereof" (Canadian Inventors)

ALEXANDRIA, Va., July 9 -- United States Patent no. 12,351,578, issued on July 8, was assigned to Ventus Therapeutics U.S. Inc. (Waltham, Mass.).

"Compounds for inhibiting NLRP3 and uses thereof" was invented by Stephane Dorich (Pointe-Claire, Canada) and Miguel St-Onge (Saint-Lazare, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):"

The patent was filed on Oct. 26, 2022, under Application No. 17/974,342.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&...